Human FGF21(Fibroblast Growth Factor 21) ELISA Kit
中文名称：人成纤维细胞生长因子21(FGF21)酶联免疫吸附测定试剂盒
Price:
- 反应性： Human
- 检测范围： 31.25-2000 pg/mL
- 灵敏度： 18.75 pg/mL
| 产品应用 | ELISA |
| 检测原理 | 本试剂盒采用双抗体夹心ELISA法。用抗人FGF21抗体包被于酶标板上，实验时样品（或标准品）中的人FGF21会与包被抗体结合。后依次加入生物素化的抗人FGF21抗体和辣根过氧化物酶标记的亲和素，抗人FGF21抗体与结合在包被抗体上的人FGF21结合，生物素与亲和素特异性结合而形成免疫复合物，游离的成分被洗去。加入显色底物(TMB)，TMB在辣根过氧化物酶的催化下呈现蓝色，加终止液后变成黄色。用酶标仪在450 nm波长处测OD值，FGF21浓度与OD450值之间呈正比，通过绘制标准曲线计算出样品中FGF21的浓度。 |
| 反应类型 | Sandwich-ELISA |
| 规格 |
96 T
/ 48 T
/ 96 T × 5
|
| 反应时间 | 3 h 30 min |
| 反应性 | Human |
| 检测方法 | 比色法;ELISA;夹心法 |
| 检测范围 | 31.25-2000 pg/mL |
| 灵敏度 | 18.75 pg/mL |
| 样本体积 | 100 μL |
| 样本类型 | 血清、血浆或其他生物体液 |
| 特异性 | 可检测样本中的人FGF21，且与其它类似物无明显交叉反应 |
| 精密度 | 板内，板间变异系数均<10% |
| 回收率 | 80%-120% |
| 储存条件 | 2-8℃ |
| 有效期 | 12个月 |
| 数据处理 |
-
Reduction of Hepatic Fat Content by Dulaglutide for the Treatment of Diabetes Mellitus: A Two-Centre Open, Single-Arm Trial
IF: 2.700Journal： Endocrinology Diabetes & Metabolism (2024)Reactivity：HumanSample Type：serum -
Predictive Value of NT-proBNP, FGF21, Galectin-3 and Copeptin in Advanced Heart Failure in Patients with Preserved and Mildly Reduced Ejection Fraction and Type 2 Diabetes Mellitus
IF: 2.400 -
Effects of low fat diet on inflammatory parameters in individuals with obesity/overweight and non-alcoholic fatty liver disease: A cross-sectional study
IF: 1.300 -
Mitochondrial metabolism related markers GDF-15, FGF-21, and HIF-1α are elevated in pediatric migraine attacks
IF: 5.000 -
Effect of fish oil supplementation on the concentration of miRNA-122, FGF-21 and liver fibrosis in patients with NAFLD: Study protocol for a randomized, double-blind and placebo-controlled clinical trial
IF: 3.000 -
Pyruvate Upregulates Hepatic FGF21 Expression by Activating PDE and Inhibiting cAMP–Epac–CREB Signaling Pathway
IF: 6.208 -
α-Lipoic acid up-regulates gene expression but reduces protein levels of fibroblast growth factor 21 in HepG2 cells
IF: 3.688 -
β-Hydroxybutyrate upregulates FGF21 expression through inhibition of histone deacetylases in hepatocytes
IF: 1.311 -
Fibroblast Growth Factor 21 Ameliorates NaV1.5 and Kir2.1 Channel Dysregulation in Human AC16 Cardiomyocytes.
IF: 5.811 -
Diagnostic Performance of Serum Biomarkers Fibroblast Growth Factor 21, Galectin-3 and Copeptin for Heart Failure with Preserved Ejection Fraction in a Sample of Patients with Type 2 Diabetes Mellitus
IF: 3.706
实验操作视频
